AMENDMENTS

In the Specification:

Please replace the paragraph beginning at page 2, line 9, with the following rewritten paragraph:

In a first aspect of the present invention there is provided a pharmaceutical aerosol foam composition including an effective amount of

a pharmaceutically active ingredient
an occlusive agent
an aqueous solvent; and
an organic cosolvent;

the pharmaceutically active ingredient being insoluble in both water and the occlusive agent; the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use.

Please replace the paragraph beginning at page 2, line 24, with the following rewritten paragraph:

The water-insoluble pharmaceutically active ingredient may be any suitable type. An analgesic such as capsaicin or piroxicam, antifungal such as clotrimazole or miconazole nitrate, antibacterial such as nitrofurazone or gramcidin, anaesthetic such as benzocaine or lidocaine, antiviral such as aciclovir or penciclovir, antipruritic such as crotamiton or phenol, antihistamine such as chlorpheniramine or triproldine, xanthine such as caffeine, sex hormone such as oestradiol or testosterone, anti-inflammatory agent or corticosteroid may be used. A corticosteroid is preferred. The corticosteroids may be selected from one or more of the group consisting of betamethasone valerate and clobetasol propionate.

Please replace the paragraph beginning at page 3, line 22, with the following rewritten paragraph:

The occlusive agent utilized in the pharmaceutical composition according to the present invention may be any excipient or combination thereof that provides an occlusive layer or hydration barrier to the skin. An occlusive layer or hydration barrier is a layer or barrier sufficient to result in reduction in trans epidermal water loss, which results in skin hydration. Suitable occlusive agents may be selected from one or more of the group consisting of mineral oils and greases, long chain acids, animal fats and greases, vegetable fats and greases, water insoluble polymers and the like. In a preferred embodiment the occlusive agent is petrolatum.



In the Claims:

Please replace claims 1, 3, 4, 6, 7 and 18 with the following versions:

Sur

1. (Amended) A pharmaceutical aerosol foam composition comprising:
an effective amount of a pharmaceutically active ingredient
an occlusive agent;
an aqueous solvent; and
an organic cosolvent

the pharmaceutically active ingredient being insoluble in both water and the occlusive agent;

the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use.



- 3. (Amended) A pharmaceutical aerosol foath composition according to Claim 2, wherein the pharmaceutically active ingredient is a corticosteroid selected from one or more of the group consisting of betamethasone valerate and clobetasol propionate.
- 4. (Amended) A pharmaceutical aerosol foam composition according to Claim 1, wherein the pharmaceutically active ingredient is present in amounts of from approximately

Serial No. 09/719,662 Docket No. 468452000300